EHA 2022: GALLIUM Final Analysis Confirms Role of Obinutuzumab in First-Line Setting for Advanced Follicular Lymphoma
Outcomes with obinutuzumab-chemotherapy were superior to rituximab-chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.